PA
PRAX icon

Perceptive Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Perceptive Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500,000
Closed -$38.5M – 103
2024
Q4 		$38.5M Buy
+500,000
New +$36.2M 1.06% 29

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's PRAX Position: Q1 2026 in Review

Perceptive Advisors increased its Praxis Precision Medicines (PRAX) stake by 2% in Q1 2026, buying an estimated $12.4M and bringing the position to 2,035,986 shares worth $656M. The position accounts for 12.82% of the portfolio, ranked #1.

Perceptive Advisors first reported a position in PRAX in Q1 2024 and has held it in 9 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Perceptive Advisors held 2,035,986 shares of Praxis Precision Medicines worth $656M as of Q1 2026.
  • Perceptive Advisors bought 40,000 Praxis Precision Medicines shares in Q1 2026, an estimated $12.4M.
  • Praxis Precision Medicines made up 12.82% of Perceptive Advisors's portfolio in Q1 2026, its #1 holding.
  • Perceptive Advisors first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 9 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.